Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis

Le Dictionnaire Vidal (2000) Vidal. Issy les Moulineaux, France Hay RJ (1994) Liposomal amphotericin B. AmBisome. J Infect 28(Suppl 1):35–43 Hiemenz JW, Walsh TJ (1996) Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 22 (Suppl 2):S133–S144 Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM et al (1985) Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis 151:704–710 Wong-Beringer A, Jacobs RA, Guglielmo BJ (1998) Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27:603–618 Lister J (1996) Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur J Haematol (Suppl 57):18–23 Herbrecht R, Letscher V, Andres E, Cavalier A (1999) Safety and efficacy of amphotericin B colloidal dispersion. An overview. Chemotherapy 45 (Suppl 1):67–76 Linden P, Williams P, Chan KM (2000) Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 14:329–339 Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P et al(1991) Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 28 (Suppl B):73–82 Rapp RP, Gubbins PO, Evans ME (1997) Amphotericin B lipid complex. Ann Pharmacother 31:1174–1186 Product insert (2000) Sporanox (itraconazole). Janssen Pharmaceutica Products, Titusville NJ Cucherat M (1997) Méta-analyse des essais thérapeutiques. Collection évaluation et statistique. Masson, Paris, p 390 Waller JL, Addy CL, Jackson KL, Garrison CZ (1994) Confidence intervals for weighted proportions. Stat Med 13:1071–1082 van’t Wout JW, Novakova I, Verhagen CA, Fibbe WE, de Pauw BE, van der Meer JW (1991) The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 22:45–52 Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 331:1325–1330 Anaissie EJ, White MH, Uzun O, Singer C, Bodey GP, Azarnia N, Lopez-Berestein G, Matzke D (1995) Abelcet (Amphotericin B lipid complex) vs amphotericin B for treatment of invasive candidiasis: a prospective, randomized multicenter trial. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract number LM-21 Abele-Horn M, Kopp A, Sternberg U, Ohly A, Dauber A, Russwurm W, Buchinger W, Nagengast O, Emmerling P (1996) A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 24:426–432 Viscoli C, Castagnola E, Van Lint MT, Moroni C, Garaventa A, Rossi MR, Fanci R, Menichetti F, Caselli D, Giacchino M, Congiu M (1996) Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 32A:814–820 Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, Williams T, Kontoyiannis DP, Karl CL, Bodey GP (1996) Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23:964–972 Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, Salit I, Miller M, Williams K, Conly JM, Singer J, Ioannou S (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 16:337–345 Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE (1997) A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 98:711–718 Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L, Sylvester R, Meis J, Boogaerts M, Selleslag D, Krcmery V, von Sinner W, MacDonald P, Doyen C, Vandercam B (1998) An EORTC international multicenter randomized trial (EORTC no. 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 27:1406–1412 Schoffski P, Freund M, Wunder R, Petersen D, Kohne CH, Hecker H, Schubert U, Ganser A (1998) Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ 317:379–384 Silling G, Fegeler W, Roos N, Boes C, Schomaker R, Essink M, Buchner T (1998) Traitement empirique précoce chez des patients neutropéniques en hématologie: étude comparative randomisée fluconazole versus amphotéricine B/5-flucytosine. Hématologie 4 (Suppl II, No. 3):19–23 Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, Cornelissen J, Herbrecht R, van der Lelie H, Hoogsteden HC, Verbrugh HA, de Marie S (1998) Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103:205–212 Malik IA, Moid I, Aziz Z, Khan S, Suleman M (1998) A randomized comparison of fluconazole with amphotericin B as empiric antifungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 105:478–483 White MH, Bowden RA, Sandler ES, Graham ML, Noskin GA, Wingard JR, Goldman M, van Burik JA, McCabe A, Lin JS, Gurwith M, Miller CB (1998) Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 27:296–302 Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764–771 Timmers GJ, Zweegman S, Simoons-Smit AM, van Loenen AC, Touw D, Huijgens PC (2000) Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 25:879–884 Sandler ES, Mustafa MM, Tkaczewski I, Graham ML, Morrison VA, Green M, Trigg M, Abboud M, Aquino VM, Gurwith M, Pietrelli L (2000) Use of amphotericin B colloidal dispersion in children. J Pediatr Hematol Oncol 22:242–246 Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31:1155–1163 Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC (2000) A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 108:282–289 Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135:412–422 Fleming RV, Kantarjian HM, Husni R, Rolston K, Lim J, Raad I, Pierce S, Cortes J, Estey E (2001) Comparison of amphotericin B lipid complex (ABLC) vs AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 40:511–520 De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N, Daunas J, Chwetzoff E (1988) The treatment of aspergillosis and aspergilloma with itraconazole: clinical results of an open international study (1982–1987). Mycoses 31:476–485 Baddour L (1999) Dosing experience with amphotericin B lipid complex (ABLC). In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster presentation Meunier F, Prentice HG, Ringden O (1991) Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 28 (Suppl B):83–91 Ringden O, Tollemar J, Dahllof G, Tyden G (1994) High cure rate of invasive fungal infections in immunocompromised children using AmBisome. Transplant Proc 26:175–177 Ringden O, Andstrom E, Remberger M, Svahn BM, Tollemar J (1994) Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 14 (Suppl 5):S10–S14 Mills W, Chopra R, Linch DC, Goldstone AH (1994) Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 86:754–760 Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A et al (1994) NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 97:135–144 Andstrom EE, Ringden O, Remberger M, Svahn BM, Tollemar J (1996) Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients. Mycoses 39:185–193 Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II, Gilbreath J, Bodey GP (1996) Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 101:170–176 Noskin G, Pietrelli L, Gurwith M, Bowden R (1999) Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients. Bone Marrow Transplant 23:697–703 Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J (1999) Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402–1407 Emminger W, Graninger W, Emminger-Schmidmeier W, Zoubek A, Pillwein K, Susani M, Wasserer A, Gadner H (1994) Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer. Ann Hematol 68:27–31 Lister J (1994) Amphotericin B lipid complex in the management of serious systemic mycoses in patients intolerant to amphotericin B therapy. In: Program and abstracts of the 36th Annual Meeting & Exposition of the American Society of Hematology. Poster number 1209 De Pauw BE, Raemaekers JM, Donnelly JP, Kullberg BJ, Meis JF (1995) An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol 70:83–87 Oppenheim BA, Herbrecht R, Kusne S (1995) The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin Infect Dis 21:1145–1153 Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA (1996) Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J Infect Dis 173:1208–1215 Troke PF (1997) Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Eur J Clin Microbiol Infect Dis 16:287–295 Mehta J, Kelsey S, Chu P, Powles R, Hazel D, Riley U, Evans C, Newland A, Treleaven J, Singhal S (1997) Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 20:39–43 Wingard JR (1997) Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 19:343–347 Kruger WH, Kroger N, Russmann B, Renges H, Kabisch H, Zander AR (1998) Treatment of mycotic infections after haemopoietic progenitor cell transplantation with liposomal amphotericin-B. Bone Marrow Transplant 22 (Suppl 4):S10–S13 Anaissie EJ, Mattiuzzi GN, Miller CB, Noskin GA, Gurwith MJ, Mamelok RD, Pietrelli LA (1998) Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion. Antimicrob Agents Chemother 42:606–611 Walsh TJ, Yeldandi V, McEvoy M, Gonzalez C, Chanock S, Freifeld A, Seibel NI, Whitcomb PO, Jarosinski P, Boswell G, Bekersky I, Alak A, Buell D, Barret J, Wilson W (1998) Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 42:2391–2398 Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ (1998) Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383–1396 Martino R, Subira M, Domingo-Albos A, Sureda A, Brunet S, Sierra J (1999) Low-dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia. Chemotherapy 45:205–212 Walsh TJ, Seibel NL, Arndt C, Harris RE, Dinubile MJ, Reboli A, Hiemenz J, Chanock SJ (1999) Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 18:702–708 Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33:e83–e90 Lequaglie C (2002) Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections. J Antimicrob Chemother 49 (Suppl 1):49–50 Tollemar J, Andersson S, Ringden O, Tyden G (1992) A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients. Mycoses 35:215–220 Clark AD, McKendrick S, Tansey PJ, Franklin IM, Chopra R (1998) A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology. Br J Haematol 103:198–204 Popp AI, White MH, Quadri T, Walshe L, Armstrong D (1999) Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study. Int J Infect Dis 3:157–160 Ringden O, Jonsson V, Hansen M, Tollemar J, Jacobsen N (1998) Severe and common side-effects of amphotericin B lipid complex (Abelcet). Bone Marrow Transplant 22:733–734 Furebring M, Oberg G, Sjolin J (2000) Side-effects of amphotericin B lipid complex (Abelcet) in the Scandinavian population. Bone Marrow Transplant 25:341–343 Utili R, Zampino R, De Vivo F, Maiello C, Andreana A, Mormone G, Marra C, Tripodi MF, Sarnataro G, Cione P, Cuccurullo S, Cotrufo M (2000) Improved outcome of pulmonary aspergillosis in heart transplant recipients with early diagnosis and itraconazole treatment. Clin Transplant 14:282–286 Barquist E, Fein E, Shadick D, Johnson J, Clark J, Shatz D (1999) A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients. J Trauma 47:336–340 Kontoyiannis DP, Andersson BS, Lewis RE, Raad II (2001) Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. Clin Infect Dis 32:e94–e96 Ellis M, Shamoon A, Gorka W, Zwaan F, al-Ramadi B (2001) Severe hepatic injury associated with lipid formulations of amphotericin B. Clin Infect Dis 32:e87–e89 Gurwith M (1999) Clinical efficacy of amphotericin B colloidal dispersion against infections caused by Aspergillus spp. Chemotherapy 45 (Suppl 1):34–38 Kontoyiannis DP, Bodey GP, Mantzoros CS (2001) Fluconazole vs amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 44:125–135 Walker RJ, Duggin GG (1988) Drug nephrotoxicity. Annu Rev Pharmacol Toxicol 28:331–345 Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41